FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W119016376> ?p ?o ?g. }

• W119016376 endingPage "55" @default.
• W119016376 startingPage "43" @default.
• W119016376 abstract "Ovarian cancer remains the number one gynecologic killer in the Western world. However, there has been significant progress in understanding the genetics of ovarian cancer and in development of more effective therapies. The current optimum approach to therapy consists of cytoreductive surgery followed by combination chemotherapy. Clinical trials have established that carboplatin plus a taxane (usually paclitaxel) can be considered to be the treatment of choice for most patients with advanced disease. Most patients will achieve a clinical complete remission with such a combination. However, the median time to progression is less than 2 years, and for patients with optimal stage III disease, median survival will be approximately 5 years. Clinical trials are currently evaluating new combination chemotherapy regimens and the role of maintenance therapy in improving time to progression and overall survival. There has been a great deal of progress in understanding the genetics of epithelial ovarian cancer. The relationship between mutations in BRCA1 and BRCA2 genes and inherited predisposition to ovarian cancer has been of major clinical importance. While 90% of ovarian cancer cases are still considered to be sporadic, identification of the molecular events associated with hereditary ovarian cancer will lead to an increased understanding of the pathogenesis of sporadic disease as well since the two diseases share many clinical features. Development of high throughput screening methodology, such as CDNA microarray analysis, will lead to identification of additional genes which are important in the development of ovarian cancer, and will help define new targets for therapy and prevention as well as potential new biomarkers for early detection. The next generation of clinical trials will be focused on evaluating chemotherapy together with new molecular therapies, such as signal transduction inhibitors, anti-angiogenesis agents, and inhibitors of matrix metalloproteinases." @default.
• W119016376 created "2016-06-24" @default.
• W119016376 creator A5075213038 @default.
• W119016376 date "2003-09-01" @default.
• W119016376 modified "2023-10-15" @default.
• W119016376 title "Progress in ovarian cancer" @default.
• W119016376 cites W120771606 @default.
• W119016376 cites W1835347798 @default.
• W119016376 cites W1863225814 @default.
• W119016376 cites W1865181509 @default.
• W119016376 cites W1922469696 @default.
• W119016376 cites W1942713680 @default.
• W119016376 cites W1970283771 @default.
• W119016376 cites W1970357063 @default.
• W119016376 cites W1972347745 @default.
• W119016376 cites W1973312028 @default.
• W119016376 cites W1976263259 @default.
• W119016376 cites W1977958507 @default.
• W119016376 cites W1989077825 @default.
• W119016376 cites W2024533570 @default.
• W119016376 cites W2037445339 @default.
• W119016376 cites W2038166913 @default.
• W119016376 cites W2041131556 @default.
• W119016376 cites W2052256709 @default.
• W119016376 cites W2059221693 @default.
• W119016376 cites W2059972525 @default.
• W119016376 cites W2069791706 @default.
• W119016376 cites W2079537409 @default.
• W119016376 cites W2080336441 @default.
• W119016376 cites W2096889436 @default.
• W119016376 cites W2097105130 @default.
• W119016376 cites W2104730351 @default.
• W119016376 cites W2128818776 @default.
• W119016376 cites W2137849078 @default.
• W119016376 cites W2141258764 @default.
• W119016376 cites W2148976855 @default.
• W119016376 cites W2151417473 @default.
• W119016376 cites W2156728001 @default.
• W119016376 cites W2169894506 @default.
• W119016376 cites W2272680342 @default.
• W119016376 cites W2273050316 @default.
• W119016376 cites W2290371619 @default.
• W119016376 cites W2319092622 @default.
• W119016376 cites W2328421677 @default.
• W119016376 cites W2338185498 @default.
• W119016376 cites W4210704032 @default.
• W119016376 cites W4237237961 @default.
• W119016376 cites W4239451229 @default.
• W119016376 cites W4253683075 @default.
• W119016376 cites W4386008674 @default.
• W119016376 doi "https://doi.org/10.1016/s1359-6349(03)00008-9" @default.
• W119016376 hasPublicationYear "2003" @default.
• W119016376 type Work @default.
• W119016376 sameAs 119016376 @default.
• W119016376 citedByCount "9" @default.
• W119016376 countsByYear W1190163762012 @default.
• W119016376 countsByYear W1190163762019 @default.
• W119016376 crossrefType "journal-article" @default.
• W119016376 hasAuthorship W119016376A5075213038 @default.
• W119016376 hasConcept C121608353 @default.
• W119016376 hasConcept C126322002 @default.
• W119016376 hasConcept C143998085 @default.
• W119016376 hasConcept C146357865 @default.
• W119016376 hasConcept C151730666 @default.
• W119016376 hasConcept C2776694085 @default.
• W119016376 hasConcept C2777292972 @default.
• W119016376 hasConcept C2777511904 @default.
• W119016376 hasConcept C2778239845 @default.
• W119016376 hasConcept C2779134260 @default.
• W119016376 hasConcept C2780427987 @default.
• W119016376 hasConcept C2781451048 @default.
• W119016376 hasConcept C530470458 @default.
• W119016376 hasConcept C535046627 @default.
• W119016376 hasConcept C60644358 @default.
• W119016376 hasConcept C71924100 @default.
• W119016376 hasConcept C86803240 @default.
• W119016376 hasConceptScore W119016376C121608353 @default.
• W119016376 hasConceptScore W119016376C126322002 @default.
• W119016376 hasConceptScore W119016376C143998085 @default.
• W119016376 hasConceptScore W119016376C146357865 @default.
• W119016376 hasConceptScore W119016376C151730666 @default.
• W119016376 hasConceptScore W119016376C2776694085 @default.
• W119016376 hasConceptScore W119016376C2777292972 @default.
• W119016376 hasConceptScore W119016376C2777511904 @default.
• W119016376 hasConceptScore W119016376C2778239845 @default.
• W119016376 hasConceptScore W119016376C2779134260 @default.
• W119016376 hasConceptScore W119016376C2780427987 @default.
• W119016376 hasConceptScore W119016376C2781451048 @default.
• W119016376 hasConceptScore W119016376C530470458 @default.
• W119016376 hasConceptScore W119016376C535046627 @default.
• W119016376 hasConceptScore W119016376C60644358 @default.
• W119016376 hasConceptScore W119016376C71924100 @default.
• W119016376 hasConceptScore W119016376C86803240 @default.
• W119016376 hasIssue "2" @default.
• W119016376 hasLocation W1190163761 @default.
• W119016376 hasOpenAccess W119016376 @default.
• W119016376 hasPrimaryLocation W1190163761 @default.
• W119016376 hasRelatedWork W1224191223 @default.

• next